Mesenchymal stem cells (MSCs)

Broker's Calls

CEO's suspension only a small bump in TalkMed's longer-term outlook, says RHB

SINGAPORE (Nov 8): RHB has downgraded its call on TalkMed Group to “neutral” from “buy” previously while raising its target price from 69 cents to 72 cents, which implies 29 times FY18F P/E.
×